Sweden's Isofol Medical reports no Q2 revenue, net loss widens

Isofol Medical AB (publ)

25/08/2026 07:09

Overview
Sweden clinical stage biotech reported no Q2 revenue and posted a net loss
Company continued clinical development of arfolitixorin, expanding trial sites in Germany
Regulatory approval granted for optimized study design and broadened inclusion criteria

Outlook
Company did not provide specific financial or operational guidance for the current or future periods

Result Drivers
CLINICAL TRIAL PROGRESS - Co cited continued advancement of arfolitixorin phase Ib/II study, including new trial sites and regulatory approvals
REGULATORY APPROVALS - Approval from German authority for optimized study design and broadened inclusion criteria enabled expansion of clinical trial

Company press release: ID:nMFN8PjKTc

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
SEK 0
 
Q2 Loss Per Share
 
SEK 0.05
 
Q2 Net Loss
 
SEK 15.73 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Isofol Medical AB (publ) is SEK1.90, about 129.2% above its August 24 closing price of SEK0.83

Reuters Recommended Reads
Aug 24 - Sweden's Episurf posts H1 loss on goodwill impairment after property expansion
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses
Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)